Moreover, a real-life cohort of patients with BRAF mutant advanced NSCLC shows that treatment with BRAF inhibitors and MEK inhibitors in BRAF V600E tumors is associated with ORR of 67%, median PFS of 5.5 months, and median OS since treatment initiation of 9.5 months, which indicate the combination of BRAF inhibitors and MEK inhibitors is clearly superior to monotherapy with a BRAF inhibitors (51). Here, BRAF is linked to non-small cell lung carcinoma.